These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22917141)

  • 21. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
    Isaac M; Vamvakas S; Abadie E; Jonsson B; Gispen C; Pani L
    Eur Neuropsychopharmacol; 2011 Nov; 21(11):781-8. PubMed ID: 21903360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma biomarkers for Alzheimer's disease: much needed but tough to find.
    Bazenet C; Lovestone S
    Biomark Med; 2012 Aug; 6(4):441-54. PubMed ID: 22917146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
    Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
    Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Donohue MC; Gamst AC; Aisen PS
    Alzheimers Dement; 2011 Mar; 7(2):245-6; author reply 247-9. PubMed ID: 21414558
    [No Abstract]   [Full Text] [Related]  

  • 25. The development of effective biomarkers for Alzheimer's disease: a review.
    Henry MS; Passmore AP; Todd S; McGuinness B; Craig D; Johnston JA
    Int J Geriatr Psychiatry; 2013 Apr; 28(4):331-40. PubMed ID: 22674539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
    Vos SJ; Visser PJ; Verhey FR
    Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unresolved questions in Alzheimer's research: will biomarkers help?
    Zetterberg H
    Biomark Med; 2014; 8(1):61-3. PubMed ID: 24325225
    [No Abstract]   [Full Text] [Related]  

  • 28. Diagnosis disclosure of prodromal Alzheimer disease-ethical analysis of two cases.
    Porteri C; Galluzzi S; Geroldi C; Frisoni GB
    Can J Neurol Sci; 2010 Jan; 37(1):67-75. PubMed ID: 20169776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new diagnostic accuracy measure and cut-point selection criterion.
    Dong T; Attwood K; Hutson A; Liu S; Tian L
    Stat Methods Med Res; 2017 Dec; 26(6):2832-2852. PubMed ID: 26486150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal cut-point definition in biomarkers: the case of censored failure time outcome.
    Rota M; Antolini L; Valsecchi MG
    BMC Med Res Methodol; 2015 Mar; 15():24. PubMed ID: 25887743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exact simultaneous confidence intervals for logical selection of a biomarker cut-point.
    Han Y; Tang SY; Lin HM; Hsu JC
    Biom J; 2022 Feb; 64(2):272-289. PubMed ID: 33634510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodological and research issues in the evaluation of biological diagnostic markers for Alzheimer's disease.
    Litvan I
    Neurobiol Aging; 1998; 19(2):121-3. PubMed ID: 9558145
    [No Abstract]   [Full Text] [Related]  

  • 33. Statistical Considerations in the Evaluation of Continuous Biomarkers.
    Polley MC; Dignam JJ
    J Nucl Med; 2021 May; 62(5):605-611. PubMed ID: 33579807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological markers of Alzheimer's disease.
    Hock C
    Neurobiol Aging; 1998; 19(2):149-51. PubMed ID: 9558152
    [No Abstract]   [Full Text] [Related]  

  • 35. What is a certified reference material?
    Mattsson N; Zetterberg H
    Biomark Med; 2012 Aug; 6(4):369-70. PubMed ID: 22917138
    [No Abstract]   [Full Text] [Related]  

  • 36. A Smooth Nonparametric Approach to Determining Cut-Points of A Continuous Scale.
    Qiu Z; Peng L; Manatunga A; Guo Y
    Comput Stat Data Anal; 2019 Jun; 134():86-210. PubMed ID: 31467457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust RNA-seq data analysis using an integrated method of ROC curve and Kolmogorov-Smirnov test.
    Yang S; Zhang K; Fang Z
    Commun Stat Simul Comput; 2022; 51(12):7444-7457. PubMed ID: 36583130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pitfalls of biomarker-based classification schemes.
    Illán-Gala I; Vilaplana E; Pegueroles J; Montal V; Alcolea D; Blesa R; Lleó A; Fortea J;
    Alzheimers Dement; 2017 Sep; 13(9):1072-1074. PubMed ID: 28704640
    [No Abstract]   [Full Text] [Related]  

  • 39. Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.
    Duarte PS
    J Nucl Med; 2021 Sep; 62(12):1833. PubMed ID: 34475238
    [No Abstract]   [Full Text] [Related]  

  • 40. Choosing the most appropriate cut-point for continuous variables.
    Tustumi F
    Rev Col Bras Cir; 2022; 49():e20223346. PubMed ID: 35894391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.